Background: The impact of nocturnal disturbance (ND) in Parkinson's disease on quality of life of patients in Western Countries is increasingly understood. Our study aimed to investigate ND prevalence and its quality of life impact in patients with advanced Parkinson's disease in China.
Methods: In a multicenter, tertiary-care hospital, outpatient-based, cross-sectional study, patients with advanced Parkinson's disease (Modified Hoehn & Yahr [H&Y] Stage II-IV with ≥3 h awake "off" time/day) from 10 tertiary hospitals throughout China completed the Parkinson's Disease Sleep Scale-2 (PDSS-2) and Parkinson's Disease Questionnaire-39 (PDQ-39).
Background: Retigabine is an antiepileptic drug developed for the adjunctive treatment of adults with epilepsy and partial-onset seizures (POS). Following its approval in 2011, reports of ophthalmological/dermatological pigmentation/discoloration led to a restriction of the indication in 2013, and in 2017, retigabine was voluntarily withdrawn from the market because of its limited usage. Here, data are reported from four open-label extension studies focusing on long-term safety with particular emphasis on ophthalmological and dermatological events.
View Article and Find Full Text PDFDiabetes mellitus is a major public health problem worldwide, and it is a known risk factor for coronary artery disease. Younger population, a group which lacks epidemiological data on diabetes mellitus, the prevalence of diabetes in them was investigated in the rural districts of north Bihar (India). Furthermore, the risk factors associated with diabetes mellitus in this younger population were also assessed.
View Article and Find Full Text PDFIntroduction: Many drugs, including serratiopeptidases, are marketed without proven efficacy in clinical trials. It is protein in nature and claimed to be effective orally.
Methods: 24 albino wistar rats, 6 each in following groups were assigned--(1) Control group (distilled water, orally) (2) Diclofenac (6.